CN113244417A - CaO2/MnFe2O4Nanocomposite material, preparation and application thereof - Google Patents
CaO2/MnFe2O4Nanocomposite material, preparation and application thereof Download PDFInfo
- Publication number
- CN113244417A CN113244417A CN202110378287.1A CN202110378287A CN113244417A CN 113244417 A CN113244417 A CN 113244417A CN 202110378287 A CN202110378287 A CN 202110378287A CN 113244417 A CN113244417 A CN 113244417A
- Authority
- CN
- China
- Prior art keywords
- cao
- mnfe
- nanoparticles
- acac
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/40—Peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/12—Macromolecular compounds
- A61K49/126—Linear polymers, e.g. dextran, inulin, PEG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Nanotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention discloses CaO2/MnFe2O4Nanocomposite and preparation thereofAnd the application, the preparation of the nano composite material: with CaCl2Adopts a one-step method to prepare PEG modified CaO2Nanoparticles; with Fe (acac)3And Mn (acac)2Preparation of MnFe as raw material2O4Nanoparticles; taking CaO2Ethanol dispersion of nanoparticles, dropwise adding MnFe2O4The CaO is obtained by ultrasonically stirring ethanol dispersion of the nano particles2/MnFe2O4A nanocomposite material. The composite material of the invention not only can be used for treating cancers by combining ion interference method and chemical kinetics therapy, but also can be used as a contrast agent of MRI to realize diagnosis and treatment. Meanwhile, the composite material has the characteristics of pH response degradation and magnetic targeting, can be metabolized out of a body, and has wide clinical application prospect in the field of biomedicine.
Description
Technical Field
The invention belongs to the technical field of nano composite particle preparation, and relates to CaO2/MnFe2O4Nanocomposite materials, their preparation and use.
Background
Malignant tumors are one of the major diseases that seriously endanger human health and are also the leading cause of death worldwide. Chemotherapy, as the most traditional treatment modality, has toxic and side effects due to low bioavailability. Under the influence of nontoxic substances released in tumors, Fenton reaction can be converted into toxic anticancer substances in situ in the tumor microenvironment, so that the cancer treatment with remarkably enhanced treatment effect and negligible toxic and side effects is realized. MnFe2O4The nano particle can convert H under neutral condition2O2Decompose to non-toxic O2And H2And O. More importantly, they can efficiently remove H under acidic conditions2O2Decompose into highly toxic hydroxyl radicals (. OH). Therefore, magnetic nanoparticles are considered as a promising tumor-targeting nanocatalysis enzyme, because hydroxyl radicals are generated in an acidic tumor microenvironment, resulting in apoptosis or necrosis of tumor cells. However, intratumoral H2O2Too low to generate significant hydroxyl radicals to achieve satisfactory catalytic therapeutic effects.
In order to overcome the defect of poor therapeutic effect of the magnetic nanoparticles, many attempts are made by those skilled in the art. For example, patent CN 202010973050.3 discloses a preparation method and application of copper sulfide/hyperbranched macromolecular nano-bionic enzyme, which uses hyperbranched macromolecular solution and CuCl2·2H2O and Na2S·9H2And preparing CuS @ G5 nano-particles by taking O as a reactant, and then sequentially preparing the GOD-loaded copper sulfide/hyperbranched macromolecular nano-bionic enzyme. According to the preparation method, a copper sulfide nanoparticle core is used as a photo-thermal agent and a Fenton-like catalyst, a hyperbranched macromolecular polymer is used as a template to wrap copper sulfide and graft glucose oxidase, and researches show that the nano bionic enzyme system has excellent chemical kinetics and photo-thermal treatment performance under the micro-acid environment of tumors. However, the product prepared in this patent is not easily degraded and the remaining material may cause damage to vital organs of the organism, resulting in organ failure and death of the organism.
Therefore, the development of the magnetic nanoparticles with good tumor treatment effect, easy degradation and good human safety has practical significance.
Disclosure of Invention
The invention aims to overcome the defect that the magnetic nanoparticles in the prior art cannot realize good consideration of tumor treatment effect and human safety, and provides the magnetic nanoparticles which have good tumor treatment effect, are easy to degrade and have good human safety.
In order to achieve the purpose, the invention provides the following technical scheme:
CaO2/MnFe2O4nanocomposite material comprising CaO2Nanoparticles and coating CaO2MnFe of the outer surface of the nanoparticles2O4Nanoparticles.
Compared with the prior art, the magnetic nano particle-MnFe2O4Nano particles, the invention introduces exogenous CaO2Thereby increasing the amount of H in the tumor2O2Due to MnFe2O4And CaO2All of which are sensitive to pH and are degraded in the tumor environment (under the acidic environment) to release a large amount of ions in the tumor environment, thereby generating hydrogen peroxide and hydroxyl radicals, and CaO2The rapid release of degraded calcium ions in the tumor microenvironment can effectively induce calcium overload and calcification, both of which are detrimental to tumor survival. The strategy of combining chemokinetic therapy and ion interference therapy (calcium ion interference method) highlights the availability of the compound in tumor treatment (obviously improves the treatment effect on tumor cells), and opens a new door for further clinical cancer treatment.
As a preferred technical scheme:
CaO as described above2/MnFe2O4Nanocomposite of said CaO2/MnFe2O4The average particle size of the nano composite material is 80-200 nm.
The invention also provides CaO as described above2/MnFe2O4The preparation method of the nano composite material comprises the following steps:
(1) with CaCl2Adopts a one-step method to prepare PEG modified CaO2Nanoparticles; CaO modified by PEG2The nano particles are stable nano particles, so that the nano particles have better dispersity, are easy to collect, are not easy to degrade and are positively charged;
specifically, CaCl is added by one-step method2Raw materials, hydrogen peroxide as an oxidant and ammonia water as an auxiliary agent are used for gradually synthesizing CaO2Nano particles, which are prepared for the next experiment;
(2) with Fe (acac)3Namely iron triacetylacetonate and Mn (acac)2Namely, manganese acetylacetonate is used as a raw material to prepare MnFe by a hydrothermal method2O4The method is mainly used for synthesizing the negatively charged nanoparticles (namely the MnFe) with the particle diameter of less than 10nm2O4Nano particles) capable of coating CaO on the surface better and more fully through electrostatic adsorption2;
(3) Taking CaO2Ethanol dispersion of nanoparticles, dropwise adding MnFe2O4Ethanol dispersion of nanoparticles, ultrasonic agitation (using ultrasonic-assisted mechanical agitation, synthesized MnFe2O4The nano-particles have magnetic characteristics, and the synthesized material can be more uniform and has good dispersibility only through mechanical stirring) to obtain the CaO2/MnFe2O4Nanocomposites, i.e. by electrostatic adsorption of MnFe2O4The nano particles coat CaO2The surface of the nano-particle makes the whole nano-composite material more sensitive to pH, thereby achieving the response and release of the tumor area.
The invention firstly synthesizes PEG modified CaO by a one-step method2Nanoparticles, then coated with MnFe2O4Nano particles, synthesis of CaO with good dispersity2@MnFe2O4The nano composite material has wide clinical application prospect in the aspects of chemokinetic therapy/ion interference method. Through the biological imaging guide and the magnetic target of the material, the multiple treatment modes are mutually cooperated, and the tumor can be completely eliminated. After treatment, the degradability of the material can reduce the toxic and side effects of the material on organisms.
As a preferred technical scheme:
the preparation method comprises the step (1) of preparing CaO by a one-step method2The process of the nano particles is specifically as follows:
taking CaCl2Dropping the mixture and PEG solution into anhydrous methanol, and adding H2O2Stirring the mixture and ammonia water (the concentration is 25 to 28 weight percent) at normal temperature, centrifuging the mixture by using ethanol, and washing the mixture to obtain CaO2And dispersing the nano particles in ethanol for later use.
Preparation method as described above, the CaCl2、PEG、H2O2And ammonia water in a ratio of (0.2 to 0.3) g: (0.5-1) mg: (1-3) mL: (0.2-0.3) mL. The protection scope of the present invention is not limited thereto, and those skilled in the art can adjust the ratio of the added amount within a certain range, but the adjustment range is not too large, for example, excessive addition of PEG will cause CaO2Nanoparticle agglomeration (i.e. CaO)2The particle size of the nano particles is increased), and further the particle size of the final material is influenced, the addition of PEG is too little, and CaO cannot be ensured2Dispersibility of the nanoparticles.
The production method as described above, in step (2), MnFe is produced2O4The process of the nano particles is specifically as follows:
taking Fe (acac)3、Mn(acac)2The oleylamine, the oleic acid and the benzyl alcohol are put into a hydrothermal reaction kettle for continuous reaction for 10 hours, and the MnFe is obtained after centrifugation and washing2O4Nanoparticles.
Preparation method as described above, Fe (acac)3、Mn(acac)2And the addition amount ratio of oleylamine, oleic acid and benzyl alcohol is (0.7-0.8) g: (0.2-0.3) g: (3-4) mL: (3-4) mL: (10-20) mL; the protection scope of the present invention is not limited thereto, and those skilled in the art can adjust the ratio of the addition amount within a certain range, but the adjustment range is not too large, such as Fe (acac)3Or Mn (acac)2If the addition amount of (A) is too large, the particle size of the final product is influenced too large; too little oleic acid will affect incomplete reaction, uneven particle size and poor dispersibility.
The temperature of the water bath heating is 180-190 ℃, and the reaction time is 8-10 h. The protection scope of the present invention is not limited thereto, and those skilled in the art can adjust the temperature and reaction time of the water bath heating within a certain range, but the adjustment range is not easy to be too large, and the excessive reaction temperature and the excessive reaction time can cause MnFe2O4The particle size of the nano particles is too large, so that agglomeration and growth are caused; the reaction temperature is too low, the reaction time is too short, the reagent can not react completely, and MnFe is influenced2O4Yield of nanoparticles.
The preparation method as described above, in the step (3), CaO2Nanoparticles and MnFe2O4The mass ratio of the nanoparticles is 10-15: 3 to 5. The scope of the present invention is not limited thereto, and those skilled in the art can apply CaO to a certain extent2Nanoparticles and MnFe2O4The mass ratio of the nano particles is adjusted, but the adjustment range is not easy to be overlarge, such as MnFe2O4If the amount of the nanoparticles added is too small, CaO will be formed2/MnFe2O4The catalytic performance and nuclear magnetism effect of the nano composite material are greatly reduced; MnFe2O4Excessive addition of nanoparticles can result in MnFe2O4The nanoparticles are free and lost during later processes.
In addition, the invention also provides CaO as described above2/MnFe2O4The application of the nano composite material in preparing tumor diagnosis and treatment reagents, chemical kinetic treatment reagents, biological imaging reagents or pH sensitive degradation reagents.
Has the advantages that:
(1) CaO of the present invention2/MnFe2O4The preparation method of the nano composite material is simple, and the synthesized nano composite material has good dispersibility and smaller particle size;
(2) CaO of the present invention2/MnFe2O4The nano composite material can realize the synergistic effect of the magnetic targeting combined chemical kinetics and the ion interference method;
(3) CaO of the present invention2/MnFe2O4The nano composite material can realize biological imaging, can degrade the pH dependently, reduces the toxic and side effects on organisms, has good tumor treatment effect and high human body safety, and has great application prospect.
Drawings
FIG. 1 shows CaO obtained in example 12/MnFe2O4Transmission electron microscopy of the nanocomposite;
FIG. 2 shows CaO obtained in example 12/MnFe2O4NanocompositeAn elemental map of the material;
FIG. 3 shows CaO obtained in example 12/MnFe2O4The particle size distribution profile of the nanocomposite;
FIG. 4 shows CaO obtained in example 12/MnFe2O4ROS plots generated by the nanocomposite at different pH;
FIG. 5 shows CaO obtained in example 12/MnFe2O4MRI imaging of the nanocomposite material;
FIG. 6 shows CaO obtained in example 12/MnFe2O4A plot of hemolysis experiments for the nanocomposite;
FIG. 7 shows CaO obtained in example 12/MnFe2O4CCK-8 diagram of the nanocomposite.
Detailed Description
The invention is described in detail below with reference to the figures and specific embodiments. The present embodiment is implemented on the premise of the technical solution of the present invention, and a detailed implementation manner and a specific operation process are given, but the scope of the present invention is not limited to the following embodiments.
In the following examples, unless otherwise specified, all the materials or treatment techniques are conventional and commercially available materials or conventional treatment techniques in the art, and NH used in the following examples3H2O is 25 to 28 wt%.
Example 1
CaO2/MnFe2O4The preparation method of the nano composite material comprises the following steps:
(1) generally, CaO2Synthesized at room temperature. 1mL of CaCl was added under vigorous stirring2(2mol/L) and 1mL of PEG (0.5mg/mL) were added to 60mL of anhydrous methanol. Thereafter, 2mL of H2O2Mixed into the above mixture and then added dropwise with 0.2mL NH three seconds later3H2And O. When the reaction lasted 2 hours, CaO was obtained by centrifugation2And washed with ethanol.
(2)MnFe2O4The nanoparticles were prepared according to a hydrothermal method.0.7285g Fe (acac)3And 0.2532g Mn (acac)2Dissolved in a mixture containing 3.0mL OA (oleic acid), 3.0mL OM (oleylamine) and 10mL benzyl alcohol. After 1 minute of sonication, the solution was reacted in an autoclave at 180 ℃ for 10 hours. The product was collected by magnetic separation and washed several times with ethanol.
(3) First, under mechanical agitation and ultrasonic treatment, 15mgCaO was added2Dissolved in 10mL of ethanol. Then 5mg MnFe2O4Dispersed in 10mL of ethanol, and the dispersion was slowly dropped into the above solution. After 6h of treatment, CaO was separated by centrifugation2/MnFe2O4The nanocomposite was washed 3 times with ethanol.
Example 2
CaO2/MnFe2O4Detecting the generated ROS of the composite nano material: the DPBF solution (130. mu.L, 1mg/mL) was added to the cuvette first, followed by 600. mu.g.ml-1CaO of (2)2/MnFe2O4The nanomaterial was compounded with PBS buffer (pH 6.5 or 7.4) to make the total reaction volume 3 ml. The absorbance of DPBF at 410nm was measured at different times.
Example 3
MRI performance testing: in vivo magnetic resonance imaging, HeLa tumor-bearing mice were injected with 200 μ L CaO2/MnFe2O4A nanocomposite material. Mice were scanned before and 3 hours after injection. A T2-weighted MRI cross-sectional scan image of the mouse was obtained.
Example 4
Hemolysis experiment: the red blood cells are washed and diluted phosphate buffer solution is mixed with CaO2/MnFe2O4The nanocomposites were kept at room temperature for 4h at different concentrations (6.25-100. mu.g/mL) and with deionized water and PBS as positive and negative controls. Then, the supernatant is obtained by centrifugation, and the hemolysis rate is determined and calculated.
Example 5
Evaluation of cytotoxicity: cells were plated at 1X 10 per well4Inoculating into 96-well plate at a density of 37 deg.C and 5% CO2Incubate for 24h under conditions. Then, using a solution containingWith different concentrations (0, 6.25, 12.5, 25, 50, 100, 200. mu.g/mL, 400. mu.g/mL) of CaO2/MnFe2O4Replacing the original culture medium with the fresh culture medium, continuously culturing for 24h, replacing the culture medium with a culture medium solution containing 10% CCK-8, continuously culturing for 1h, and detecting the OD value (the detection wavelength is 450nm) of each well on an enzyme-labeling instrument.
The final products synthesized in the above examples were characterized as shown in fig. 1 to 7:
as can be seen from the transmission electron microscope of FIG. 1 and the mapping of FIG. 2, CaO was successfully synthesized2/MnFe2O4Nano material and small grain size.
As is clear from the particle size diagram in FIG. 3, CaO2/MnFe2O4The particle size of (A) is uniform and the hydrated particle size is about 150 nm.
As can be seen from FIG. 4, CaO2/MnFe2O4Compared with pH7.4, the nanocomposite generates more ROS in PBS buffer solution with pH6.5, which indicates that the nanocomposite degrades under acidic condition and can effectively generate a large amount of ROS to kill tumor cells.
As can be seen from FIG. 5, the nanocomposite CaO2/MnFe2O4The nuclear magnetic signal in the tumor area is obvious, which indicates that the nano composite material is suitable to be used as an MRI imaging contrast agent for MRI imaging.
As can be seen from the hemolysis experiment of FIG. 6, the material CaO2/MnFe2O4The hemolysis rate of (2) is low, which shows that the material has excellent biocompatibility and water solubility and can be used for in vivo experiments.
As can be seen from the CCK-8 experiment of FIG. 7a, normal cells and high CaO concentration2/MnFe2O4The survival rate is still about 80% when the materials are cultivated, and the low toxicity of the materials is proved. As can be seen from FIG. 7b, the survival rate of tumor cells at pH6.5 was significantly lower than that at pH7.4 when the material was incubated with tumors of different pH, demonstrating that the material had a good effect of killing tumor cells in an acidic response.
Example 6
CaO2/MnFe2O4The preparation method of the nano composite material comprises the following steps:
(2) generally, CaO2Synthesized at room temperature. Under vigorous stirring, 1mL of CaCl2(2mol/L) and 1mL of PEG (0.5mg/mL) were added to 60mL of anhydrous methanol. Thereafter, 1mL of H2O2Mixed into the above mixture and then added dropwise with 0.2mL NH three seconds later3H2And O. When the reaction lasted 2 hours, CaO was obtained by centrifugation2And washed with ethanol.
(2)MnFe2O4The nanoparticles were prepared according to a hydrothermal method. 0.73g Fe (acac)3And 0.26gMn (acac)2Dissolved in a mixture containing 3.0mL OA (oleic acid), 3.0mL OM (oleylamine) and 10mL benzyl alcohol. After 1 minute of sonication, the solution was reacted in an autoclave at 180 ℃ for 10 hours. The product was collected by magnetic separation and washed several times with ethanol.
(3) First, 10mgCaO was added under mechanical agitation and ultrasonic treatment2Dissolved in 10mL of ethanol. Then 3mgMnFe2O4Dispersed in 10mL of ethanol, and the dispersion was slowly dropped into the above solution. After 6h of treatment, CaO was separated by centrifugation2/MnFe2O4The nanocomposite was washed 3 times with ethanol.
Example 7
CaO2/MnFe2O4The preparation method of the nano composite material comprises the following steps:
(1) generally, CaO2Synthesized at room temperature. Under vigorous stirring, 1mL of CaCl2(2.1mol/L) and 1mL of PEG (0.5mg/mL) were added to 60mL of anhydrous methanol. Thereafter, 2mL of H2O2Mixed into the above mixture and then added dropwise with 0.3mL of NH three seconds later3H2And O. When the reaction lasted 2 hours, CaO was obtained by centrifugation2And washed with ethanol.
(2)MnFe2O4The nanoparticles were prepared according to a hydrothermal method. Mixing 0.75g Fe (acac)3And 0.26gMn (acac)2Dissolved in a solution containing 3.0mLOA (oleic acid), 3.0mL OM (oleylamine) and 10mL benzyl alcohol. After 1 minute of sonication, the solution was reacted in an autoclave at 180 ℃ for 10 hours. The product was collected by magnetic separation and washed several times with ethanol.
(3) Firstly, under mechanical stirring and ultrasonic treatment, 15mg CaO is added2Dissolved in 10mL of ethanol. Then 5mg MnFe2O4Dispersed in 10mL of ethanol, and the dispersion was slowly dropped into the above solution. After 6h of treatment, CaO was separated by centrifugation2/MnFe2O4The nanocomposite was washed 3 times with ethanol.
Example 8
CaO2/MnFe2O4The preparation method of the nano composite material comprises the following steps:
(1) generally, CaO2Synthesized at room temperature. Under vigorous stirring, 1mL of CaCl2(2mol/L) and 2mL of PEG (0.5mg/mL) were added to 60mL of anhydrous methanol. After that, 3mL of H2O2Mixed into the above mixture and then added dropwise with 0.3mL of NH three seconds later3H2And O. When the reaction lasted 2 hours, CaO was obtained by centrifugation2And washed with ethanol.
(2)MnFe2O4The nanoparticles were prepared according to a hydrothermal method. 0.73g Fe (acac)3And 0.25gMn (acac)2Dissolved in a mixture containing 3.0mL OA (oleic acid), 3.0mL LOM (oleylamine) and 10mL benzyl alcohol. After 1 minute of sonication, the solution was reacted in an autoclave at 180 ℃ for 10 hours. The product was collected by magnetic separation and washed several times with ethanol.
(3) First, under mechanical agitation and ultrasonic treatment, 15mgCaO was added2Dissolved in 10mL of ethanol. Then 5mg MnFe2O4Dispersed in 10mL of ethanol, and the dispersion was slowly dropped into the above solution. After 6h of treatment, CaO was separated by centrifugation2/MnFe2O4The nanocomposite was washed 3 times with ethanol.
The embodiments described above are described to facilitate an understanding and use of the invention by those skilled in the art. It will be readily apparent to those skilled in the art that various modifications to these embodiments may be made, and the generic principles described herein may be applied to other embodiments without the use of the inventive faculty. Therefore, the present invention is not limited to the above embodiments, and those skilled in the art should make improvements and modifications within the scope of the present invention based on the disclosure of the present invention.
Claims (10)
1.CaO2/MnFe2O4Nanocomposite material, characterized in that it comprises CaO2Nanoparticles and coating CaO2MnFe of the outer surface of the nanoparticles2O4Nanoparticles.
2. CaO according to claim 12/MnFe2O4Nanocomposite material, characterized in that said CaO2/MnFe2O4The average particle size of the nano composite material is 80-200 nm.
3. CaO according to claim 1 or 22/MnFe2O4The preparation method of the nano composite material is characterized by comprising the following steps:
(1) with CaCl2Adopts a one-step method to prepare PEG modified CaO2Nanoparticles;
(2) with Fe (acac)3And Mn (acac)2Preparation of MnFe as raw material2O4Nanoparticles;
(3) taking CaO2Ethanol dispersion of nanoparticles, dropwise adding MnFe2O4The CaO is obtained by ultrasonically stirring ethanol dispersion of the nano particles2/MnFe2O4A nanocomposite material.
4. The method according to claim 3, wherein CaO is prepared in one step in step (1)2The process of the nano particles is specifically as follows:
taking CaCl2Dropping with PEG solutionAdding H into anhydrous methanol2O2Mixing with ammonia water, stirring at normal temperature, centrifuging with ethanol, and washing to obtain CaO2And dispersing the nano particles in ethanol for later use.
5. The method of claim 4, wherein the CaCl is2、PEG、H2O2And ammonia water in a ratio of (0.2 to 0.3) g: (0.5-1) mg: (1-3) mL: (0.2-0.3) mL.
6. The method according to claim 3, wherein in the step (2), MnFe is prepared2O4The process of the nano particles is specifically as follows:
taking Fe (acac)3、Mn(acac)2The oleylamine, the oleic acid and the benzyl alcohol are put into a hydrothermal reaction kettle for continuous reaction for 10 hours, and the MnFe is obtained after centrifugation and washing2O4Nanoparticles.
7. The method according to claim 6, wherein the Fe (acac)3、Mn(acac)2And the addition amount ratio of oleylamine, oleic acid and benzyl alcohol is (0.7-0.8) g: (0.2-0.3) g: (3-4) mL: (3-4) mL: (10-20) mL;
the temperature of the water bath heating is 180-190 ℃, and the reaction time is 8-10 h.
8. The method according to claim 3, wherein in the step (3), CaO is added2Nanoparticles and MnFe2O4The mass ratio of the nanoparticles is 10-15: 3 to 5.
9. CaO according to claim 1 or 22/MnFe2O4Use of a nanocomposite material for the preparation of a chemokinetic therapeutic agent, a bioimaging agent or a pH sensitive degradation agent.
10. CaO according to claim 1 or 22/MnFe2O4The application of the nano composite material in preparing a tumor diagnosis and treatment reagent.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110378287.1A CN113244417B (en) | 2021-04-08 | 2021-04-08 | CaO 2 /MnFe 2 O 4 Nanocomposite material, preparation and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110378287.1A CN113244417B (en) | 2021-04-08 | 2021-04-08 | CaO 2 /MnFe 2 O 4 Nanocomposite material, preparation and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113244417A true CN113244417A (en) | 2021-08-13 |
CN113244417B CN113244417B (en) | 2023-03-28 |
Family
ID=77220455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110378287.1A Active CN113244417B (en) | 2021-04-08 | 2021-04-08 | CaO 2 /MnFe 2 O 4 Nanocomposite material, preparation and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113244417B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116077659A (en) * | 2023-04-11 | 2023-05-09 | 山东大学 | Microminiature Janus nano particle and preparation method and application thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106966484A (en) * | 2017-03-31 | 2017-07-21 | 常州大学 | A kind of nanometer Fe3O4/CaO2The method for repairing the pollution of underground water benzene homologues |
CN109317162A (en) * | 2018-11-14 | 2019-02-12 | 扬州大学 | A kind of efficiently heterogeneous class fenton catalyst MnFe2O4/SiO2Preparation method |
CN110179818A (en) * | 2019-05-27 | 2019-08-30 | 河北大学 | CaO2@DOX@ZIF-67 nano material and the preparation method and application thereof |
CN112294751A (en) * | 2020-10-31 | 2021-02-02 | 郑州大学 | Preparation method and application of calcium peroxide-loaded metal organic framework pharmaceutical composition |
CN113134012A (en) * | 2021-03-04 | 2021-07-20 | 江苏大学 | CaO2/Fe3O4@ OA nano composite and preparation method and application thereof |
-
2021
- 2021-04-08 CN CN202110378287.1A patent/CN113244417B/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106966484A (en) * | 2017-03-31 | 2017-07-21 | 常州大学 | A kind of nanometer Fe3O4/CaO2The method for repairing the pollution of underground water benzene homologues |
CN109317162A (en) * | 2018-11-14 | 2019-02-12 | 扬州大学 | A kind of efficiently heterogeneous class fenton catalyst MnFe2O4/SiO2Preparation method |
CN110179818A (en) * | 2019-05-27 | 2019-08-30 | 河北大学 | CaO2@DOX@ZIF-67 nano material and the preparation method and application thereof |
CN112294751A (en) * | 2020-10-31 | 2021-02-02 | 郑州大学 | Preparation method and application of calcium peroxide-loaded metal organic framework pharmaceutical composition |
CN113134012A (en) * | 2021-03-04 | 2021-07-20 | 江苏大学 | CaO2/Fe3O4@ OA nano composite and preparation method and application thereof |
Non-Patent Citations (7)
Title |
---|
BINBIN DING ET AL.: "MnFe2O4-decorated large-pore mesoporous silica-coated upconversion nanoparticles for near-infrared light-induced and O2 self-sufficient photodynamic therapy", 《NANOSCALE》 * |
FEI CHEN ET AL.: "A CaO2@Tannic Acid-FeIII Nanoconjugate for Enhanced Chemodynamic Tumor Therapy", 《CHEMMEDCHEM》 * |
MENG ZHANG ET AL.: "Calcium-Overload-Mediated Tumor Therapy by Calcium Peroxide Nanoparticles", 《CHEM》 * |
WANG ET AL.: "Removal of norfloxacin by surface Fenton system (MnFe2O4/H2O2):Kinetics, mechanism and degradation pathway", 《CHEMICAL ENGINEERING JOURNAL》 * |
YINGJIE SHENG ET AL.: "Oxygen generating nanoparticles for improved photodynamic therapy of hypoxic tumours", 《JOURNAL OF CONTROLLED RELEASE》 * |
ZHIQIANG WEI ET AL.: "Hydrothermal synthesis and photo-Fenton degradation of magnetic MnFe2O4/rGO nanocomposites", 《JOURNAL OF MATERIALS SCIENCE》 * |
热分解法制备 MNFE2O4 纳米粒子及其超顺磁性: "尤娜 等", 《物理实验》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116077659A (en) * | 2023-04-11 | 2023-05-09 | 山东大学 | Microminiature Janus nano particle and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN113244417B (en) | 2023-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107349211B (en) | Hollow MnO2Composite nano material, preparation method and application thereof | |
Bian et al. | Cu-based MOFs decorated dendritic mesoporous silica as tumor microenvironment responsive nanoreactor for enhanced tumor multimodal therapy | |
CN110680926B (en) | Nano diagnosis and treatment agent and preparation method and application thereof | |
CN107242996B (en) | A kind of gel rubber material and preparation method thereof for oncotherapy | |
CN110819339B (en) | Cu-amino acid composite up-conversion nano material and preparation method thereof | |
CN109289050B (en) | Ferroferric oxide/polypyrrole/glucose oxidase composite multifunctional nano diagnosis and treatment agent and preparation method and application thereof | |
CN112807430A (en) | Application of nano enzyme-based material | |
CN110755640B (en) | Preparation method and application of gold-platinum composite nano diagnosis and treatment agent | |
CN113244417B (en) | CaO 2 /MnFe 2 O 4 Nanocomposite material, preparation and application thereof | |
CN107469094B (en) | Nano material for magnetic resonance imaging and/or photothermal therapy and preparation method thereof | |
CN110882389B (en) | Titanium monoxide nano material and preparation method and application thereof | |
CN110559438B (en) | Photothermal and photodynamic diagnosis and treatment integrated reagent guided by nuclear magnetic resonance imaging and preparation method thereof | |
CN109550050B (en) | Melanin-loaded molybdenum dioxide drug-loaded compound and preparation and application thereof | |
CN114159588B (en) | Ternary alloy PtW-Mn-based nano probe, preparation method and application thereof | |
CN115518154A (en) | FeCuNC nano material and preparation and application thereof | |
CN114949186A (en) | POD-GOD (peroxidase-GOD) synergistically modified mesoporous silicon nanomaterial, preparation method and application | |
CN110917172B (en) | Molybdenum oxide nanosheet plugging hollow mesoporous silicon nanomaterial and preparation and application thereof | |
CN116196438B (en) | Preparation method of oxidation-responsive nano preparation | |
CN114939162B (en) | Multifunctional nano catalyst for ultrasonic-mediated bio-orthogonal reaction and preparation method and application thereof | |
CN114246946B (en) | Nanometer contrast agent for diagnosis and treatment integration and preparation method thereof | |
CN114225030B (en) | Co-carried Fe 3+ Glucose oxidase, nano-cluster mesoporous dopamine nano-particles, and preparation method and application thereof | |
CN117883473A (en) | Hollow ferrocobalt hydroxide nano enzyme and preparation method and application thereof | |
CN114869909B (en) | Anti-tumor therapeutic agent based on free radicals and preparation method and application thereof | |
CN116785429A (en) | Functionalized modified copper sulfide/cuprous oxide heterojunction nanocomposite and preparation method and application thereof | |
CN115025050A (en) | Degradable ferric oxide nano-microsphere for enhancing anti-tumor therapy through cascade reaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |